Free tool
FAERS Monitor: Kuvan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022181 or its brand name (Kuvan, Sapropterin Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,907
Serious
1,042
18% of reports
Hospitalization
415
Death reported
72
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective358
- headache358
- therapy non-responder356
- vomiting291
- maternal exposure during pregnancy281
- diarrhoea269
- nausea218
- amino acid level increased209
- abdominal pain upper198
- anxiety184
- abdominal discomfort166
- cough150
- arthralgia148
- dizziness147
- nasopharyngitis141
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 31 |
| 2009 | 99 |
| 2010 | 194 |
| 2011 | 66 |
| 2012 | 57 |
| 2013 | 50 |
| 2014 | 356 |
| 2015 | 387 |
| 2016 | 459 |
| 2017 | 564 |
| 2018 | 521 |
| 2019 | 726 |
| 2020 | 583 |
| 2021 | 550 |
| 2022 | 340 |
| 2023 | 332 |
| 2024 | 308 |
| 2025 | 175 |
| 2026 | 109 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,252 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amino acid level increasedSignal | 209 | 1394.6 | 1190.9 | 208,191 |
| therapy non-responderSignal | 356 | 28.4 | 25.7 | 9,336 |
| maternal exposure during pregnancySignal | 281 | 11.3 | 10.0 | 2,619 |
| abdominal discomfortSignal | 166 | 3.5 | 3.0 | 300 |
| abdominal pain upperSignal | 198 | 3.4 | 3.0 | 341 |
| nasopharyngitisSignal | 141 | 2.7 | 2.3 | 153 |
| anxietySignal | 184 | 2.3 | 2.0 | 136 |
| vomitingSignal | 291 | 2.2 | 2.0 | 195 |
| headacheSignal | 358 | 2.0 | 1.8 | 193 |
| cough | 150 | 1.9 | 1.6 | 64 |
| diarrhoea | 269 | 1.5 | 1.3 | 43 |
| arthralgia | 148 | 1.3 | 1.1 | 8 |
| dizziness | 147 | 1.0 | 0.9 | 0 |
| nausea | 218 | 1.0 | 0.9 | 0 |
| drug ineffective | 358 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.